The 7 Biomarkers That Actually Predict Your Healthspan (Ranked by Effect Size)
Most "longevity panels" sold today test 100+ markers. The peer-reviewed literature suggests something different: roughly seven biomarkers explain the bulk of all-cause mortality variance for adults aged 35-65. The rest is noise, novelty, or marketing.
This is the shortlist — ranked by effect size in published cohorts, with target values by age and sex, the realistic timeline to move each, and the markers we deliberately excluded. If you only have time to track seven things, track these.
We've ordered the list by hazard ratio (HR) for all-cause mortality reported in the strongest available cohort studies. Effect sizes vary by population and follow-up length, so treat the ranking as directional rather than absolute.
Why most longevity panels are noise
The longevity testing market has a discoverability problem disguised as a coverage problem. Function Health bundles 100+ markers for breadth. Lifeforce runs a recurring 50+ marker subscription. Bryan Johnson's Blueprint publishes hundreds of N=1 measurements. Each is internally consistent. None tells you what to fix first.
A 100-marker panel is a noise generator if you don't know which signals carry predictive weight. Statistically, most longevity-adjacent biomarkers are correlated — fix the upstream drivers and a dozen downstream readouts move with them. Testing all twelve doesn't add information; it adds anxiety and overhead.
Peter Attia's Outlive framework is closer to right — small set, ranked by effect, anchored to peer-reviewed literature — but it's largely paywalled inside a book and a subscription podcast. Bryan Johnson's protocol is the opposite failure mode: maximally public, but it's an N=1 optimization run, not a generalizable map.
What follows is the generalizable shortlist. Each marker meets three criteria: (1) reproducible association with all-cause mortality in cohorts of 10,000+ adults, (2) modifiable through lifestyle or pharmacology, and (3) measurable through standard clinical testing. We did not include markers that are intellectually interesting but clinically inactionable for an asymptomatic 40-year-old.
If you want the underlying philosophy of fixing your single weakest input rather than chasing all of them, see our companion piece on identifying your health bottleneck.
The 7 biomarkers, ranked
#1 — VO2 max
VO2 max — your maximal rate of oxygen utilization during exercise, expressed in ml/kg/min — is the single largest modifiable predictor of all-cause mortality in the published literature. In a Cleveland Clinic cohort of 122,007 patients followed for a median of 8.4 years, individuals in the lowest cardiorespiratory fitness quintile had a hazard ratio of approximately 5.04 for all-cause mortality versus elite-fit peers. The mortality gradient between "below average" and "above average" was larger than the gradient between smoking and not smoking [1].
The American Heart Association formally recommends treating cardiorespiratory fitness as a clinical vital sign [2]. Most clinics still don't measure it.
VO2 max normative values (ml/kg/min, ~75th percentile, treadmill)
| Age | Male | Female |
|---|---|---|
| 30-39 | 46 | 38 |
| 40-49 | 42 | 34 |
| 50-59 | 38 | 31 |
| 60-69 | 34 | 27 |
Target: ≥75th percentile for your age and sex. "Elite" (≥90th percentile) is associated with the strongest mortality reduction but has diminishing returns above the 75th percentile in most cohorts.
How to move it: The training prescription is unambiguous — 3-4 hours per week of Zone 2 (conversational pace, ~70-75% max heart rate) plus 1-2 sessions of high-intensity intervals (4x4 minutes at 90-95% max heart rate). Twelve weeks of structured training reliably adds 3-5 ml/kg/min in untrained adults.
For testing protocols and a full age/sex normative table, see VO2 max by age.
#2 — ApoB
Apolipoprotein B (ApoB) counts the number of atherogenic lipoprotein particles in your blood. Every LDL, VLDL, IDL, and Lp(a) particle carries exactly one ApoB. It is the most direct measure of your atherosclerotic cardiovascular disease (ASCVD) risk available in standard bloodwork.
LDL-C — the "bad cholesterol" number on every standard lipid panel — measures the cholesterol cargo inside LDL particles, not the particle count. Two patients with identical LDL-C can have very different ApoB. The patient with more particles has higher ASCVD risk regardless of cholesterol concentration. Sniderman and colleagues demonstrated that ApoB outperforms both LDL-C and non-HDL-C as a predictor of cardiovascular events in pooled analyses of 233,455 individuals [3]. The Marston 2022 analysis of 389,529 UK Biobank participants confirmed ApoB as the principal driver of ASCVD risk [4].
Targets
- Primary prevention (no prior event): <60 mg/dL for adults concerned with longevity; <80 mg/dL is the conservative clinical threshold
- Secondary prevention (prior event, diabetic, or high lifetime risk): <50 mg/dL
How to move it: Statins reduce ApoB by 25-45%. PCSK9 inhibitors add another 25-35%. Diet-only reductions (saturated fat restriction, soluble fiber, plant sterols) typically deliver 10-15%. For high-risk patients, the math favors pharmacology.
Deeper dive: ApoB target and treatment thresholds.
#3 — Grip strength
Grip strength is the most under-measured longevity biomarker in clinical practice. It's free, takes 30 seconds with a hand dynamometer, and outperforms blood pressure as a mortality predictor in some cohorts.
The PURE study (Leong et al., Lancet 2015) followed 139,691 adults across 17 countries. Each 5 kg decrease in grip strength was associated with a 16% increase in all-cause mortality (HR 1.16, 95% CI 1.13-1.20), independent of physical activity, smoking, and socioeconomic status [5].
Grip strength is a proxy for total muscle mass and neuromuscular function — both of which independently predict survival, particularly past age 60.
Grip strength normative values (kg, ~75th percentile, dominant hand)
| Age | Male | Female |
|---|---|---|
| 30-39 | 50 | 30 |
| 40-49 | 48 | 29 |
| 50-59 | 45 | 27 |
| 60-69 | 40 | 24 |
Target: ≥75th percentile for your age and sex.
How to move it: Grip-specific training (deadlifts, farmer's carries, dead hangs, heavy rows) adds 5-8 kg in 12 weeks for untrained adults. Compound lifts beat grip-isolation work. If your grip strength is below the 50th percentile, this is likely your highest-leverage intervention.
More: Grip strength and mortality.
#4 — HbA1c
Hemoglobin A1c is a 90-day average of your blood glucose. It's the cleanest single proxy for metabolic health that exists in standard bloodwork.
The clinical reference range tops out at 5.7% for "normal" (>5.7% = prediabetes, ≥6.5% = diabetes). The longevity-optimal target is tighter. The EPIC-Norfolk cohort (n=10,232, 6 years follow-up) showed a continuous mortality gradient starting at 5.0% — every 1-percentage-point increase in HbA1c was associated with a 28% increase in all-cause mortality among non-diabetic adults [6].
Targets
- Optimal: <5.3%
- Acceptable: 5.3-5.6%
- Action required: ≥5.7%
How to move it: -0.3 to -0.5% in 12 weeks is realistic with reduced refined carbohydrate intake, daily Zone 2 cardio (which improves insulin sensitivity acutely), and resistance training (which expands the glucose-disposal sink). Sleep and stress also matter — chronic short sleep raises HbA1c independent of diet.
#5 — Lp(a)
Lipoprotein(a) is a genetically determined ApoB-containing particle. Your level is set at birth, stays roughly constant through life, and is unaffected by diet, exercise, or statins. Roughly 20% of the global population has elevated Lp(a), and most don't know it. This is the highest-yield "test once, never again" marker on the list.
Tsimikas (2017) and the Copenhagen General Population Study established Lp(a) as a causal, independent risk factor for ASCVD and aortic stenosis [7]. Risk rises continuously above 30 mg/dL and steeply above 50 mg/dL.
Targets
- Optimal: <30 mg/dL
- Borderline: 30-50 mg/dL
- High risk: 50-180 mg/dL — aggressive ApoB control warranted
- Very high risk: >180 mg/dL — emerging Lp(a)-lowering therapies (pelacarsen, olpasiran) in late-stage trials
How to use it: You can't lower Lp(a) with current standard-of-care. Instead, an elevated Lp(a) result should ratchet down your acceptable ApoB threshold. Someone with Lp(a) of 100 mg/dL should treat ApoB to <50 mg/dL even without other risk factors.
#6 — Visceral adiposity
BMI is dead as a longevity marker. It conflates muscle and fat, ignores fat distribution, and routinely misclassifies athletic adults as overweight while marking sarcopenic-obese adults as healthy. Waist circumference and visceral adipose tissue (VAT) — the fat surrounding internal organs — are the metabolically dangerous fat.
Visceral fat is endocrinologically active. It secretes inflammatory cytokines, drives insulin resistance, and is independently associated with cardiovascular events, several cancers, and all-cause mortality, even after adjusting for total body fat [8].
Targets
- Waist circumference: <94 cm men, <80 cm women (WHO thresholds)
- DEXA visceral fat mass: <1.0 kg (ideally <0.5 kg)
A simple field test: waist-to-height ratio <0.5. "Keep your waist under half your height."
How to move it: -2 to -5% body fat in 12 weeks is realistic with a 300-500 kcal/day deficit plus resistance training to preserve lean mass. Visceral fat preferentially mobilizes early in a deficit — the first kilograms lost are disproportionately the dangerous ones.
#7 — hs-CRP
High-sensitivity C-reactive protein measures low-grade systemic inflammation. The JUPITER trial established hs-CRP as an independent predictor of cardiovascular events even in patients with normal LDL-C [9]. Chronic elevation correlates with ASCVD, several cancers, neurodegenerative disease, and all-cause mortality.
Targets
- Optimal: <0.7 mg/L
- Acceptable: 0.7-1.0 mg/L
- Borderline: 1.0-3.0 mg/L
- Action required: >3.0 mg/L (if not from acute infection)
How to move it: hs-CRP is a downstream readout, not a primary lever. -50 to -70% reduction in 12 weeks is achievable when the upstream root cause is addressed. Most common drivers, in order of frequency: chronic short sleep, periodontal disease (get a dental cleaning), gut dysbiosis, visceral adiposity, and undiagnosed autoimmune activity. Re-test 6 weeks after addressing the suspected driver.
What's NOT on the list — and why
The longevity testing industry profits from breadth. Here are the markers we deliberately excluded, with the literature behind each exclusion.
Telomere length tests. Telomere length has weak individual-level reproducibility — the same patient tested twice often gets different results. Predictive power for individual mortality is modest at best. Useful for population research, not for personal decisions. Save the $200.
Most "biological age" calculators. PhenoAge and GrimAge are scientifically interesting and outperform chronological age in epidemiological cohorts [10]. But for an individual patient deciding what to do this quarter, they offer no actionable signal beyond what the underlying inputs (which include several markers on this list) already provide. The tests are downstream of what you can change — fix the inputs and the "biological age" follows.
Continuous glucose monitors for non-diabetics. No mortality data exists for CGM use in healthy adults. Glucose variability is real; whether tracking it weekly changes outcomes for someone with HbA1c <5.5% is unestablished. Currently a hype-cycle product.
Comprehensive hormone panels for asymptomatic adults. High false-positive rate, frequent over-treatment, no demonstrated mortality benefit when applied to asymptomatic patients. If you have symptoms (fatigue, libido changes, mood disruption), test. If you don't, don't.
Resting heart rate alone. RHR correlates with VO2 max and is essentially redundant once you've measured fitness directly. Useful as a daily trend in wearable data; not useful as a standalone biomarker.
The 4-step longevity audit
Skip the 100-marker panel. Run this four-step audit instead.
1. Test the seven. Six of the seven are accessible through standard bloodwork plus a tape measure: ApoB, HbA1c, Lp(a) (one-time), hs-CRP, and waist circumference. Grip strength requires a $30 hand dynamometer or your gym's. VO2 max requires either a CPET (cardiopulmonary exercise test, ~$200-400 at most performance clinics) or a validated submaximal estimate from a treadmill/bike test. Total cost for the full panel: typically under $500 if you don't already have recent labs.
2. Score each against the age- and sex-adjusted optimal. Use the targets in this article. Don't compare to the lab's reference range — clinical reference ranges are population norms (the middle 95%), not longevity-optimal targets. "Normal" labs frequently include sub-optimal values.
3. Identify your weakest one or two — your bottlenecks. Most adults have one dominant weak signal that explains their elevated risk. The marginal hour spent improving your strongest marker is wasted; the same hour spent on your weakest marker is high-leverage. This is the bottleneck principle Feroce is built around.
4. Re-test in 90 days. Twelve weeks is the minimum interval for meaningful change in HbA1c, ApoB, hs-CRP, VO2 max, grip strength, and visceral fat. Earlier re-testing measures noise. Lp(a) does not need re-testing.
The realistic timeline for moving each marker
Effect-size and speed of change for each marker, assuming structured intervention and a baseline-adult starting point:
| Marker | Realistic 12-week change | Primary lever |
|---|---|---|
| VO2 max | +3-5 ml/kg/min | Z2 cardio + 1-2 HIIT sessions/week |
| ApoB | -25-50 mg/dL (statin or PCSK9); -10-15 mg/dL (nutrition only) | Pharmacology > diet for high-risk |
| Grip strength | +5-8 kg | Compound lifts + grip-specific work |
| HbA1c | -0.3 to -0.5% | Reduce refined carbs, daily Z2, resistance training |
| Lp(a) | ~0 (genetic) | Manage downstream — tighter ApoB target |
| Visceral adiposity | -2 to -5% body fat | 300-500 kcal/day deficit + strength training |
| hs-CRP | -50 to -70% if root cause addressed | Sleep, periodontal, gut, visceral fat |
A realistic first year: pick the weakest two markers, run a 12-week protocol on each, re-test, repeat. By month 12 you've materially moved 4 markers — which is more than most "comprehensive longevity programs" achieve in three years of subscription billing.
FAQ
Should I get a longevity panel?
Not the 100-marker version. Run the seven biomarkers in this article through your existing primary care physician or a direct-to-consumer lab (Marek Health, Quest, Labcorp). Total cost is typically $300-500 versus $1,500-3,000 for branded longevity panels — and you'll get actionable signal instead of a coffee-table report.
VO2 max — how do I test it?
Three tiers, descending in accuracy. Gold standard: CPET (cardiopulmonary exercise test) at a performance medicine clinic — direct measurement via gas exchange, $200-400. Good: validated submaximal protocols (e.g., Cooper test, Bruce protocol with HR-based estimate) at most gyms. Acceptable: Apple Watch / Garmin estimates, which correlate moderately with measured VO2 max but are best used for tracking change in yourself, not absolute classification.
Is biological age testing worth it?
For an individual making decisions about training, nutrition, and pharmacology — no. The underlying inputs (most of which are on this list of seven) give you actionable signal. PhenoAge and GrimAge are scientifically valuable for population research, not for personal protocol decisions.
How does Feroce compare to Attia or Lifeforce?
Attia provides the framework but operates inside a book + paid podcast. Lifeforce sells subscription bloodwork with limited interpretation. Feroce is built around the bottleneck principle — identifying which of your inputs (sleep, nutrition, stress, movement, hormones, microbiome, mental health, environment) is the limiting factor on your specific healthspan trajectory, then giving you a daily AI coach that adapts to your wearable data. Less breadth, more leverage.
What's the cheapest way to test the seven?
Standard bloodwork via your primary care covers ApoB ($30), HbA1c ($30), Lp(a) ($50, one-time), and hs-CRP ($30). A tape measure is free for waist circumference. A used hand dynamometer is $25 for grip strength. The only meaningful cost is VO2 max ($200-400 for CPET; ~$0 for a wearable estimate). Total under $500 if you start from scratch.
The bottom line
Seven biomarkers. Ranked by effect size in peer-reviewed cohorts. Measurable through standard clinical testing. Each modifiable through lifestyle or pharmacology in a 12-week window.
The longevity industry will keep selling 100-marker panels and biological age scores. The published literature keeps pointing to the same shortlist. Test the seven. Score against the age-adjusted optimal. Fix your weakest one. Re-test in 90 days.
If you want a system that does steps 2-4 for you continuously — pulling your wearable data, your labs, and your symptoms into a single longevity protocol that adapts week-by-week — start with Feroce. We built it because the shortlist exists, and almost nobody is helping you act on it.
Citations
[1] Mandsager K, et al. Association of Cardiorespiratory Fitness With Long-term Mortality Among Adults Undergoing Exercise Treadmill Testing. JAMA Network Open. 2018;1(6):e183605. https://pubmed.ncbi.nlm.nih.gov/30646252/
[2] Ross R, et al. Importance of Assessing Cardiorespiratory Fitness in Clinical Practice: A Case for Fitness as a Clinical Vital Sign. Circulation. 2016;134(24):e653-e699. https://pubmed.ncbi.nlm.nih.gov/27881567/
[3] Sniderman AD, et al. Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. JAMA Cardiology. 2019;4(12):1287-1295. https://pubmed.ncbi.nlm.nih.gov/31642874/
[4] Marston NA, et al. Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis. JAMA Cardiology. 2022;7(3):250-256. https://pubmed.ncbi.nlm.nih.gov/34773460/
[5] Leong DP, et al. Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study. Lancet. 2015;386(9990):266-273. https://pubmed.ncbi.nlm.nih.gov/25982160/
[6] Khaw KT, et al. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Annals of Internal Medicine. 2004;141(6):413-420. https://pubmed.ncbi.nlm.nih.gov/15381514/
[7] Tsimikas S. A Test in Context: Lipoprotein(a) — Diagnosis, Prognosis, Controversies, and Emerging Therapies. Journal of the American College of Cardiology. 2017;69(6):692-711. https://pubmed.ncbi.nlm.nih.gov/28183512/
[8] Neeland IJ, et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes & Endocrinology. 2019;7(9):715-725. https://pubmed.ncbi.nlm.nih.gov/31301983/
[9] Ridker PM, et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein (JUPITER). New England Journal of Medicine. 2008;359:2195-2207. https://pubmed.ncbi.nlm.nih.gov/18997196/
[10] Levine ME, et al. An epigenetic biomarker of aging for lifespan and healthspan. Aging. 2018;10(4):573-591. https://pubmed.ncbi.nlm.nih.gov/29676998/
[11] López-Otín C, et al. The Hallmarks of Aging. Cell. 2013;153(6):1194-1217. https://pubmed.ncbi.nlm.nih.gov/23746838/
[12] López-Otín C, et al. Hallmarks of aging: An expanding universe. Cell. 2023;186(2):243-278. https://pubmed.ncbi.nlm.nih.gov/36599349/
[13] Strain T, et al. Wearable-device-measured physical activity and future health risk. Nature Medicine. 2020;26:1385-1391. https://pubmed.ncbi.nlm.nih.gov/32807930/
[14] Kodama S, et al. Cardiorespiratory fitness as a quantitative predictor of all-cause mortality and cardiovascular events in healthy men and women: a meta-analysis. JAMA. 2009;301(19):2024-2035. https://pubmed.ncbi.nlm.nih.gov/19454641/
[15] Ference BA, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. European Heart Journal. 2017;38(32):2459-2472. https://pubmed.ncbi.nlm.nih.gov/28444290/
Built into the product
Stop reading. Start fixing.
Feroce reads your wearable, your bloodwork, your habits, and texts you the one move that matters today. Sequenced over weeks. On WhatsApp. Until you operate at full capacity.
Find my bottleneck →